HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hiles, J. J. Articles by Kolesar, J. M. Search for Related Content PubMed PubMed Citation Articles by Hiles, J. J. Articles by Kolesar, J. M.

JON J. HILES, PHARM.D., is Pharmacy Practice Resident, Clarian Health Partners, Indianapolis, IN; at the time of writing he was Pharm.D. candidate, School of Pharmacy, University of Wisconsin (UW), Madison. JILL M. KOLESAR, PHARMD., BCPS, FCCP, is Associate Professor, School of Pharmacy, and Faculty Supervisor, Paul P. Carbone Comprehensive Cancer Center, UW.

Address correspondence to Dr. Kolesar at the Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin, 600 Highland Avenue, Room K4/554, Madison, WI 53705 (jmkolesar{at}pharmacy.wisc.edu).

Purpose. The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Summary. Sunitinib malate is a potent inhibitor of vascular endothelial growth factor (VEGF) receptors, FMS-like tyrosine kinase 3 (FLT3), c-KIT, and platelet-derived growth factor (PDGF), which give the drug its direct antitumor and antiangiogenic properties. Sunitinib is currently approved as a second-line treatment of mRCC in patients who have either not responded to or who are not eligible to receive interleukin-2. Clinical trials of sunitinib have found similar rates of partial response, disease stabilization, and progression-free survival. Sorafenib inhibits VEGF receptors, PDGF receptors, FLT3, RAF-1, and BRAF in vitro and has been shown to prevent the growth of tumors but not to reduce tumor size. Sorafenib has been proven to improve survival in a novel randomized discontinuation trial and a Phase III randomized, placebo-controlled trial. No studies have directly compared the effectiveness of sunitinib to sorafenib in the treatment of advanced renal cell carcinoma. Sunitinib and sorafenib share a similar mechanism of action and primarily target tumor angiogenesis by inhibiting a variety of tyrosine kinases; the agents have similar toxicity, with the exception of an increased risk of hypertension associated with the use of sorafenib. Sorafenib does not result in tumor shrinkage, but sunitinib significantly reduces tumor size. Conclusion. The tyrosine kinase inhibitors sorafenib and sunitinib offer improved outcomes for patients with mRCC, but they are far short of a cure. Despite the introduction of sorafenib and sunitinib, palliative care is still an acceptable treatment option for mRCC because of the disease’s extremely poor prognosis. Index terms: Antineoplastic agents; Carcinoma; Mechanism of action; Sorafenib; Sunitinib; Toxicity

 

This article has been cited by other articles:

				A. D. Smith, M. L. Lieber, and S. N. Shah Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT Am. J. Roentgenol., January 1, 2010; 194(1): 157 - 165. [Abstract] [Full Text] [PDF]

				J. Y. Kwon, K. W. Lee, J.-E. Kim, S. K. Jung, N. J. Kang, M. K. Hwang, Y.-S. Heo, A. M. Bode, Z. Dong, and H. J. Lee Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MAPKK4 and PI-3 kinase Carcinogenesis, November 1, 2009; 30(11): 1932 - 1940. [Abstract] [Full Text] [PDF]

				F. Honecker, H. Wermann, F. Mayer, A. J.M. Gillis, H. Stoop, R. J.L.M. van Gurp, K. Oechsle, E. Steyerberg, J. Th. Hartmann, W. N.M. Dinjens, et al. Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors J. Clin. Oncol., May 1, 2009; 27(13): 2129 - 2136. [Abstract] [Full Text] [PDF]

				N. Kumar, R. Afeyan, H.-D. Kim, and D. A. Lauffenburger Multipathway Model Enables Prediction of Kinase Inhibitor Cross-Talk Effects on Migration of Her2-Overexpressing Mammary Epithelial Cells Mol. Pharmacol., June 1, 2008; 73(6): 1668 - 1678. [Abstract] [Full Text] [PDF]